Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in the 24th Annual Needham Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, April 9, 2025, at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST.

An audio webcast of the discussion will be accessible through the Investors section of Jazz Pharmaceuticals' website, with replays available for 30 days. The company, headquartered in Dublin, Ireland, is a global biopharma organization focused on developing life-changing medicines for patients with serious diseases, particularly in areas with therapeutic options.

Jazz maintains a diverse portfolio including:

• Leading therapies for sleep disorders and epilepsy
• Growing portfolio of cancer treatments
• Innovative therapeutics pipeline in oncology and neuroscience

DUBLIN, March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24^th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 9, 2025, at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST.

An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors: 
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-302412294.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When is Jazz Pharmaceuticals (JAZZ) presenting at the Needham Healthcare Conference 2025?

Jazz Pharmaceuticals will present on Wednesday, April 9, 2025, at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST.

How long will Jazz Pharmaceuticals' (JAZZ) Needham Conference webcast be available for replay?

The webcast replay will be archived on Jazz Pharmaceuticals' investor website for 30 days.

What are the main therapeutic areas in Jazz Pharmaceuticals' (JAZZ) current portfolio?

Jazz Pharmaceuticals' portfolio includes leading therapies for sleep disorders and epilepsy, plus a growing portfolio of cancer treatments.

Where can investors access Jazz Pharmaceuticals' (JAZZ) Needham Conference presentation?

Investors can access the audio webcast through the Investors section of Jazz Pharmaceuticals' website at investor.jazzpharma.com.

What are the key focus areas of Jazz Pharmaceuticals' (JAZZ) R&D pipeline?

Jazz Pharmaceuticals' R&D pipeline focuses on innovative therapeutics in oncology and neuroscience.